329 related articles for article (PubMed ID: 14720024)
1. Cefepime: a review of its use in the management of hospitalized patients with pneumonia.
Chapman TM; Perry CM
Am J Respir Med; 2003; 2(1):75-107. PubMed ID: 14720024
[TBL] [Abstract][Full Text] [Related]
2. Clinical applications of a new parenteral antibiotic in the treatment of severe bacterial infections.
Holloway WJ; Palmer D
Am J Med; 1996 Jun; 100(6A):52S-59S. PubMed ID: 8678098
[TBL] [Abstract][Full Text] [Related]
3. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
[TBL] [Abstract][Full Text] [Related]
4. Ceftaroline fosamil in the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections.
Lodise TP; Low DE
Drugs; 2012 Jul; 72(11):1473-93. PubMed ID: 22779432
[TBL] [Abstract][Full Text] [Related]
5. Ceftriaxone: an update of its use in the management of community-acquired and nosocomial infections.
Lamb HM; Ormrod D; Scott LJ; Figgitt DP
Drugs; 2002; 62(7):1041-89. PubMed ID: 11985490
[TBL] [Abstract][Full Text] [Related]
6. Cefepime. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.
Barradell LB; Bryson HM
Drugs; 1994 Mar; 47(3):471-505. PubMed ID: 7514976
[TBL] [Abstract][Full Text] [Related]
7. Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.
Zhanel GG; Lam A; Schweizer F; Thomson K; Walkty A; Rubinstein E; Gin AS; Hoban DJ; Noreddin AM; Karlowsky JA
Am J Clin Dermatol; 2008; 9(4):245-54. PubMed ID: 18572975
[TBL] [Abstract][Full Text] [Related]
8. A new therapeutic option for the treatment of pneumonia.
McCabe R; Chirurgi V; Farkas SA; Haddow A; Heinz G; Greene S
Am J Med; 1996 Jun; 100(6A):60S-67S. PubMed ID: 8678099
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
Jones RN; Sader HS; Fritsche TR; Pottumarthy S
Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923
[TBL] [Abstract][Full Text] [Related]
10. Cefepime microbiologic profile and update.
Kessler RE
Pediatr Infect Dis J; 2001 Mar; 20(3):331-6. PubMed ID: 11303846
[TBL] [Abstract][Full Text] [Related]
11. Cefepime: a new fourth-generation cephalosporin.
Okamoto MP; Nakahiro RK; Chin A; Bedikian A; Gill MA
Am J Hosp Pharm; 1994 Feb; 51(4):463-77; quiz 541-2. PubMed ID: 8017411
[TBL] [Abstract][Full Text] [Related]
12. Comparative in vitro activity of cefepime against nosocomial isolates.
Sofianou D; Tsoulfa S; Kontodimou L; Polydorou F; Malaka E
J Chemother; 1997 Oct; 9(5):341-6. PubMed ID: 9373789
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of cefepime versus ceftazidime in the treatment of adult pneumonia.
Lin JC; Yeh KM; Peng MY; Chang FY
J Microbiol Immunol Infect; 2001 Jun; 34(2):131-7. PubMed ID: 11456359
[TBL] [Abstract][Full Text] [Related]
14. Cefdinir: a review of its use in the management of mild-to-moderate bacterial infections.
Perry CM; Scott LJ
Drugs; 2004; 64(13):1433-64. PubMed ID: 15212560
[TBL] [Abstract][Full Text] [Related]
15. Activity of cefepime compared with other antibiotics against gram-positive bacteria and cefuroxime-resistant gram-negative bacteria.
Wang FD; Liu IM; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 1998 Jul; 61(7):408-13. PubMed ID: 9699393
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group.
Jones RN; Pfaller MA; Doern GV; Erwin ME; Hollis RJ
Diagn Microbiol Infect Dis; 1998 Mar; 30(3):215-28. PubMed ID: 9572029
[TBL] [Abstract][Full Text] [Related]
17. A multicenter comparative study of cefepime versus broad-spectrum antibacterial therapy in moderate and severe bacterial infections.
Badaró R; Molinar F; Seas C; Stamboulian D; Mendonça J; Massud J; Nascimento LO;
Braz J Infect Dis; 2002 Oct; 6(5):206-18. PubMed ID: 12495602
[TBL] [Abstract][Full Text] [Related]
18. Bacteriologic and clinical applications of a new extended-spectrum parenteral cephalosporin.
Segreti J; Levin S
Am J Med; 1996 Jun; 100(6A):45S-51S. PubMed ID: 8678097
[TBL] [Abstract][Full Text] [Related]
19. In-vitro activity of cefepime and other broad-spectrum antimicrobials against several groups of gram-negative bacilli and Staphylococcus aureus.
Tallis E; Rudensky B; Attias D; Raveh D; Schlesinger Y; Yinnon AM
Diagn Microbiol Infect Dis; 1999 Oct; 35(2):121-6. PubMed ID: 10579092
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species.
Sanders WE; Tenney JH; Kessler RE
Clin Infect Dis; 1996 Sep; 23(3):454-61. PubMed ID: 8879764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
